In the third episode of the KDIGO Conversations in Nephrology FSGS series, host Dr. Kirk Campbell (University of Pennsylvania) sits down with world-renowned glomerular disease expert Dr. Jai Radhakrishnan (Columbia University) to navigate the shifting landscape of Focal Segmental Glomerulosclerosis (FSGS) management.

The conversation dives deep into the diagnostic complexities of FSGS, moving beyond histological patterns to understand the diverse drivers of podocyte injury. Dr. Radhakrishnan shares his practical clinical algorithm, offering a roadmap for balancing supportive care, selective immunosuppression, and the integration of novel, non-immunosuppressive therapies. Join Drs. Campbell and Radhakrishnan as they discuss the robust pipeline of emerging agents in this field.

In this second episode of the three-part KDIGO Conversations in Nephrology series, Dr. Kirk Campbell speaks with Dr. Laura Mariani about the central role of proteinuria reduction in the management of focal segmental glomerulosclerosis (FSGS).

The discussion explores the biologic link between podocyte injury and proteinuria, the goals and findings of the PARASOL initiative, and how proteinuria may help guide clinical trial design and treatment decisions in FSGS. Dr. Mariani also reflects on the importance of collaboration and data sharing in advancing therapies for rare glomerular diseases.

Join Dr. Kirk Campbell (University of Pennsylvania) and Dr. Alessia Fornoni (University of Miami) for an in-depth conversation on the evolving landscape of Focal Segmental Glomerulosclerosis (FSGS).

The first episode of this three-part FSGS series explores the transition from traditional histological classifications to a more precise clinical and molecular understanding of the disease. Dr. Campbell and Dr. Fornoni discuss the definition and pathogenesis of FSGS as well as clinical management and the future of treatment.

In this episode of KDIGO Conversations in Nephrology, Dr. Kirk Campbell speaks with Dr. Alessia Fornoni about the evolving understanding of focal segmental glomerulosclerosis (FSGS) as a podocytopathy driven by podocyte injury. The discussion explores advances in FSGS classification, the role of angiotensin II and endothelin-1 signaling in disease progression, emerging insights into disease mechanisms, and how new targeted therapies may help preserve podocyte function and slow the progression of kidney disease.

This episode is part of a special three-part KDIGO Conversations in Nephrology series exploring advances in podocyte biology, disease mechanisms, emerging therapies, and the evolving clinical management of FSGS.

This final episode in KDIGO’s four-part IgAN series focuses on the challenges and opportunities of implementing the updated KDIGO IgAN Guideline in clinical practice.

The conversation examines a shifting treatment paradigm that emphasizes earlier intervention and simultaneous, multi-targeted therapy, while addressing persistent barriers to guideline adoption, including gaps in disease awareness, diagnostic precision, and risk stratification.

Drawing on insights from recent clinical trials, the discussion also explores how emerging evidence is shaping therapeutic decision-making, highlights priority areas for future IgAN research, and considers what continued innovation may mean for improving long-term patient outcomes.

The episode is hosted by Dana Rizk, MD (University of Alabama at Birmingham, US), and features Suneel Udani, MD (Nephrology Associates of Northern Illinois and Indiana, US). Previous episodes in the series feature KDIGO IgAN Guideline Co-Chair Brad Rovin, MD (The Ohio State University College of Medicine, US), Shikha Wadwani, MD (Cedars Sinai, US), Andrew Lazar, MD (University Hospitals of Cleveland, US), and Gaia Coppock, MD (University of Pennsylvania Medicine, US).

This podcast series was supported by Travere.

This third episode in KDIGO’s four-part IgAN series explores how to apply KDIGO guidance in real-world IgAN care through two illustrative patient cases. Building on earlier episodes in the series, the discussion highlights dynamic risk assessment, treatment selection, and monitoring strategies, along with practical decisions about RAS inhibitors versus DEARAs, TRF-budesonide versus systemic glucocorticoids, and the use of SGLT2 inhibitors. The episode also addresses complex scenarios, including rapidly progressive glomerulonephritis, nephrotic syndrome, acute kidney injury, pediatric IgAN, pregnancy, and treatment considerations in resource-limited settings.

The episode is hosted by Dana Rizk, MD (University of Alabama at Birmingham, US), and features Gaia Coppock, MD (University of Pennsylvania Medicine, US), and Andrew Lazar, MD (University Hospitals of Cleveland, US). Previous episodes in the series feature KDIGO IgAN Guideine Co-Chair Brad Rovin, MD (The Ohio State University College of Medicine, US), and Shikha Wadwani, MD (Cedars-Sinai, US). The fourth and final episode will be released in December 2025 and will focus on the challenges of implementing evidence-based guidance, emerging therapies, and key research needs.

This podcast series was supported by Travere.

In the final episode of KDIGO’s three-part Conversations in Nephrology series on APOL1 kidney disease, host Kirk Campbell, MD (University of Pennsylvania, United States), speaks with Titilayo Ilori, MD (Boston University, United States), and kidney health advocate Joshua Albright (United States) about how APOL1 genetic testing can shape the future of kidney care. Their conversation brings together clinical expertise and lived experience to examine why early detection matters, how to overcome barriers to equitable testing, and what it will take to turn awareness into meaningful action for patients and communities.

Learn more and access resources from the KDIGO Controversies Conference on APOL1 Kidney Disease: https://kdigo.org/conferences/apol1-kidney-disease/

This podcast was supported by Vertex Pharmaceuticals.

In this second installment of KDIGO’s three-part podcast series on APOL1 kidney disease, host Kirk Campbell, MD (University of Pennsylvania, United States), welcomes Barry Freedman, MD (Wake Forest University School of Medicine, United States) for a practical discussion on patient management.

They examine how APOL1 risk variants influence progression, review current therapeutic approaches, and explore emerging targeted treatments designed to improve care and outcomes for affected individuals.

Learn more and access resources from the KDIGO Controversies Conference on APOL1 Kidney Disease: https://kdigo.org/conferences/apol1-kidney-disease/

This podcast was supported by Vertex Pharmaceuticals.

This is the first episode of a three-part KDIGO Conversations in Nephrology series on APOL1 kidney disease. Host Kirk Campbell, MD (University of Pennsylvania, United States), speaks with Bessie Young, MD (University of Washington, United States) about the discovery, burden, and biology of APOL1 kidney disease. Their discussion explores how APOL1 variants contribute to increased kidney disease risk in people of African ancestry, recent findings on protective variants, and ongoing research toward targeted therapies.

Learn more and access resources from the KDIGO Controversies Conference on APOL1 Kidney Disease: https://kdigo.org/conferences/apol1-kidney-disease/

This podcast was supported by Vertex Pharmaceuticals.